Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia
- 15 July 2019
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 33 (11), 2751-2753
- https://doi.org/10.1038/s41375-019-0516-7
Abstract
No abstract availableFunding Information
- Science and Technology Support Program of Jiangsu Province (BE2017639, BE2016643)
- Jiangsu Province Key Medical Talents
This publication has 7 references indexed in Scilit:
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellNature Medicine, 2018
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemiaAmerican Journal of Hematology, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patientsLeukemia, 2017
- Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemiaBlood, 2017
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2014
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013